Download PDF
CC BY 4.0 · Pharmaceutical Fronts 2022; 04(03): e157-e161
DOI: 10.1055/s-0042-1749327
Original Article

Synthesis and Characterization of Related Substances of Torasemide

Jiong Chen
1   Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, People's Republic of China
,
Wei Ming
1   Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, People's Republic of China
,
De-Hua Fan
2   Wuhan Jianuokang Pharmaceutical Technology Co., Ltd., Wuhan, People's Republic of China
,
Shuang-Xi Gu
1   Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, People's Republic of China
3   Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Wuhan Institute of Technology, Wuhan, People's Republic of China
› Author Affiliations Funding The supports from the National Natural Science Foundation of China (Grant No. 21877087 and 22074114), the Hubei Provincial Department of Education of China (Grant No. 2021CFB556 and 2020CFB623), Key Laboratory for Green Chemical Process of Ministry of Education (Grant No. GCP20200201), Hubei Key Laboratory of Novel Reactor and Green Chemical Technology (Grant No. 40201002), and Wuhan Institute of Technology Teaching Research Project (Grant No. X2017034) are gratefully acknowledged.
› Further Information
   Permissions and Reprints

Abstract

Torasemide, a pyridine-3-sulfonylurea derivative, is a high-efficiency loop diuretic. During the process development of torasemide, five process-related substances, which have been specified in the pharmacopeia, would be produced. In this study, all these related substances, including compounds A–E, were synthesized via simple procedures and subsequently characterized by 1H nuclear magnetic resonance (NMR), 13C NMR, and mass spectrometry. Particularly, a simple synthetic method for compound A has not been found in previous literature. It is worth noting that other related substances could be prepared from compound B in one or two steps. The availability of these related substances could allow for quality control in the process of torasemide.

Keywords

torasemide - loop diuretic - related substances - synthesis - process development

Supplementary Material



Publication History

Received: 18 February 2022

Accepted: 23 April 2022

Article published online:
30 June 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Szekely G, Amores de Sousa MC, Gil M, Castelo Ferreira F, Heggie W. Genotoxic impurities in pharmaceutical manufacturing: sources, regulations, and mitigation. Chem Rev 2015; 115 (16) 8182-8229
    CrossrefPubMedGoogle Scholar
  • 2 Tang P, Nie B, Huang JZ, Zhang YJ, Zhang J, Chen FE. Recent advances of pharmaceutical process chemistry and its innovation in China: part 1. Pharm Fronts 2020; 2 (01) e28-e54
    Article in Thieme ConnectGoogle Scholar
  • 3 Yue Y, Luo XF, Zhong WY, Hou W. Advances in researches on impurities in chemical drugs. Prog Pharm Sci 2015; 39 (07) 533-539
    Google Scholar
  • 4 Kang JL. Discussion on impurity profile analysis of synthetic drug substances. Carol J Pharm 2016; 47 (08) 1093-1096
    Google Scholar
  • 5 Dongbang S, Confair DN, Ellman JA. Rhodium-catalyzed C-H alkenylation/electrocyclization cascade provides dihydropyridines that serve as versatile intermediates to diverse nitrogen heterocycles. Acc Chem Res 2021; 54 (07) 1766-1778
    CrossrefPubMedGoogle Scholar
  • 6 Kaldas SJ, O'Keefe KTV, Mendoza-Sanchez R, Yudin AK. Amphoteric borylketenimines: versatile intermediates in the synthesis of borylated heterocycles. Chem Eur J 2017; 23 (41) 9711-9715
    CrossrefPubMedGoogle Scholar
  • 7 Liu XY, Shen JF. Progress in clinical research on a new diuretic torasemide. Shanghai Med Pharm J 2007; 28 (05) 219-221
    Google Scholar
  • 8 Hua L, Li YS, Song Z. Torasemide, a new loop diuretics. Chin J New Drug 2003; 12 (11) 888-892
    Google Scholar
  • 9 Stirling A, Fisher M. Torasemide. Pract Diabetes 2018; 35 (03) 106-107
    CrossrefGoogle Scholar
  • 10 Manolis A, Kallistratos M, Doumas M. Torasemide in hypertension and heart failure: re-inventing loop diuretic therapy?. Curr Pharm Des 2021; 27 (23) 2714-2721
    CrossrefPubMedGoogle Scholar
  • 11 Arie G, Marina E, Dmitry G. et al. Process for the preparation of highly pure torsemide. WO Patent 2003097603A1. November, 2003
    PubMedGoogle Scholar
  • 12 Che DQ, Guntoori BR, Duncan SC. Process for the preparation of torsemide and related intermediates. U.S. Patent 7378527B2. September, 2005
    PubMedGoogle Scholar
  • 13 Wei WY, Huo LR, Yang XB. et al. Method for preparing torasemide and its derivatives. CN Patent 104744355A. July, 2015
    PubMedGoogle Scholar
  • 14 Xiong ZH, Fei XN. Synthesis of a new, curative and effective medicine for hypertension and diuretic torasemide. Chinese J Med Chem 2002; 12 (04) 219-221
    Google Scholar
  • 15 Zhang LW, Shu Q, Yin L. et al. A process for preparing torasemide and its crystal forms. CN Patent 102702089A. October, 2012
    PubMedGoogle Scholar
  • 16 Zhao SM, Shang JP, Li Q, Luo ZF. Study on synthesis of torasemid. Fine Chem Intermed 2009; 39 (06) 29-30
    Google Scholar
  • 17 Masereel B, Renard P, Schynts M, Pirotte B, de Tullio P, Delarge J. Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na+ 2C1− K+ cotransporter inhibitors. Eur J Med Chem 1994; 29 (07) 527-535
    CrossrefGoogle Scholar
  • 18 Bozdag M, Alafeefy AM, Altamimi AM, Vullo D, Carta F, Supuran CT. Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity. Bioorg Med Chem 2017; 25 (02) 677-683
    CrossrefPubMedGoogle Scholar
  • 19 Ismail MA, Abou El Ella DA, Abouzid KA, Mahmoud AH. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. Bioorg Med Chem 2012; 20 (07) 2455-2478
    CrossrefPubMedGoogle Scholar
  • 20 Venkatesh Y, Nandi S, Shee M, Saha B. Bis-acetyl carbazole: a photoremovable protecting group for sequential release of two different functional groups and its application in therapeutic release. Eur J Org Chem 2017; (41) 6121-6130
    CrossrefGoogle Scholar